Jun 1 2015
Bexion Pharmaceuticals LLC announced that the Small Business Administration (SBA) has awarded the Company the prestigious Tibbetts Award, recognizing Bexion as a "Model of Excellence" for the Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Awarded to less than two dozen companies nationwide in 2015, Bexion joins an elite group of companies that have excelled through SBIR/STTR investment.
The 2015 Tibbetts Award recipients will be formally honored at a White House ceremony and at the June 16 kickoff of the National SBIR/STTR Conference, where thousands of the best and brightest in the innovation ecosystem convene annually.
"Bexion's development progression of our cancer therapeutic from early drug discovery to a planned Phase I First in Human Study was substantially fueled by the SBIR/STTR program," said Dr. Ray Takigiku, Founder and CEO of Bexion. "As a recipient of 5 SBIR awards from the National Cancer Institute (NCI) at NIH and matching Phase I and Phase II SBIR grants from the Kentucky Cabinet for Economic Development, Office of Entrepreneurship, Bexion has judiciously leveraged those resources to advance our drug to the clinic."
SOURCE Bexion Pharmaceuticals LLC
Tertiary lymphoid structures linked to improved outcomes in liver cancer patients